Well, that's one take on it, the other is the ASX doesn't know shit from clay. Telix is considerably undervalued and so is Neuren. Neuren's 2591 asset isn't even priced in and it's the crown jewel of the company potentially worth billions.
CUV's revenues still rising which is good to see, only a nihilist would see it as anything other than positive. But questions linger over execution and conflicts of interest concerning the CEO. If vitiligo is approved, that will go some way to assuaging concerns that this company IS able to conduct large Phase 3 trials and bodes well for the other indications (Parkinson's et al). I would consider that a major inflection point and the opportunity to leave the misery of the last decade behind.
Well, that's one take on it, the other is the ASX...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.76 |
Change
0.350(2.27%) |
Mkt cap ! $790.7M | |||
| Open | High | Low | Value | Volume |
| $15.16 | $15.98 | $15.03 | $1.670M | 106.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 108 | $15.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.77 | 280 | 3 |
View Market Depth
| Last trade - 13.57pm 30/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |